Overall market sentiment has been high on Lexaria Bioscience Corp (LEXX) stock lately. LEXX receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.
Lexaria Bioscience Corp has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on LEXX!
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With LEXX Stock Today?
Lexaria Bioscience Corp (LEXX) stock is trading at $1.03 as of 9:50 AM on Friday, Oct 13, a gain of $0.05, or 5.1% from the previous closing price of $0.98. Volume today is more active than usual. So far 300,682 shares have traded compared to average volume of 44,241 shares. The stock has traded between $1.01 and $1.11 so far today.
To screen for more stocks like Lexaria Bioscience Corp click here.
More About Lexaria Bioscience Corp
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio.
Click Here to get the full Stock Report for Lexaria Bioscience Corp stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
